％0期刊文章ukena，d％威兴者，c％a engelstatter，施泰·尼斯，v％sybrecht，毒蕈碱m1-受体选择性拮抗剂，Telenzepine，Copd患者没有支气管扩张作用％D 1993％J欧洲呼吸期刊％p 378-382％p 378-382％v 6％n 3％x在双盲，安慰剂控制，随机，交叉试验中，我们研究了毒蕈碱m1受体选择性拮抗剂的影响(+/-)-telenzepine (3 mg orally at 6 p.m. for 5 days) in 21 patients with chronic obstructive pulmonary disease (COPD). At enrollment all patients showed at least a 50% decrease in airway resistance (Raw) after inhalation of 400 micrograms fenoterol or 200 micrograms oxitropium bromide. Telenzepine did not have a significant effect on forced expiratory volume in one second (FEV1) or forced vital capacity (FVC). Also, no significant changes could be detected in daily spirometric profiles or Raw. The results indicate that short-term treatment with the M1-selective antagonist, telenzepine, does not improve airway function in COPD patients, at least after administration by the oral route. %U //www.qdcxjkg.com/content/erj/6/3/378.full.pdf